ALK INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ALK plus NON-SMALL CELL LUNG CANCER (NSCLC): UPDATED EFFICACY AND SAFETY DATA

被引：20
|
作者：
Gettinger, S. [1 ]
Bazhenova, L. [2 ]
Salgia, R. [3 ]
Langer, C. [4 ]
Gold, K. [5 ]
Rosell, R. [6 ]
Shaw, A. [7 ]
Weiss, G. J. [8 ]
Narasimhan, N. I. [9 ]
Dorer, D. J. [10 ]
Rivera, V. M. [11 ]
Clackson, T. [12 ]
Haluska, F. G. [13 ]
Camidge, R. [14 ]
机构：
[1] Yale Univ, Sch Med, Thorac Oncol Program, New Haven, CT USA
[2] UCSD Moores Canc Ctr, La Jolla, CA USA
[3] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA
[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] USP Dexeus Univ Inst, Inst Oncol Dr Rosell, Med Oncol Serv, Barcelona, Spain
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
[8] Scottsdale Healthcare, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[9] ARIAD Pharmaceut Inc, DMPK, Cambridge, MA USA
[10] ARIAD Pharmaceut Inc, Biostat, Cambridge, MA USA
[11] ARIAD Pharmaceut, Preclin & Translat Res, Cambridge, MA USA
[12] ARIAD Pharmaceut Inc, Res & Dev, Cambridge, MA USA
[13] ARIAD Pharmaceut Inc, Clin Res & Dev, Cambridge, MA USA
[14] Univ Colorado, Div Med Oncol, Denver, CO 80202 USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu349.71
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1292P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated efficacy and safety of the ALK inhibitor AP26113 in patients (pts) with advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Camidge, D. Ross
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK plus non-small cell lung cancer (NSCLC).
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice Tsang
    Weiss, Glen J.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Timothy Piers
    Conlan, Maureen G.
    Kerstein, David
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Efficacy and safety of AP26113 in ALK+ non-small cell lung cancer (NSCLC), including patients with brain metastases
    Gettinger, S. N.
    Bazhenova, L.
    Salgia, R.
    Langer, C. J.
    Gold, K. A.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Narasimhan, N. I.
    Dorer, D. J.
    Rivera, V. M.
    Clackson, T.
    Haluska, F. G.
    Camidge, D. R.
    LUNG CANCER, 2015, 87 : S32 - S32
  • [4] EVALUATION OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR BRIGATINIB [AP26113] IN PATIENTS (PTS) WITH ALK plus NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES
    Kerstein, D.
    Gettinger, S.
    Gold, K.
    Langer, C. J.
    Shaw, A. T.
    Bazhenova, L. A.
    Salgia, R.
    Dorer, D. J.
    Conlan, M. G.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [5] PHASE 1/2 STUDY OF AP26113 IN PATIENTS (PTS) WITH ADVANCED MALIGNANCIES, INCLUDING ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC): ANALYSIS OF SAFETY AND EFFICACY AT SELECTED PHASE 2 DOSES
    Rosell, R.
    Gettinger, S.
    Bazhenova, L. A.
    Langer, C. J.
    Salgia, R.
    Gold, K.
    Shaw, A. T.
    Dorer, D. J.
    Kerstein, D.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [6] Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results
    Gettinger, Scott N.
    Bazhenova, Lyudmila
    Salgia, Ravi
    Langer, Corey J.
    Gold, Kathryn A.
    Rosell, Rafael
    Shaw, Alice
    Weiss, Glen J.
    Dorer, David J.
    Rivera, Victor M.
    Conlan, Maureen G.
    Kerstein, David
    Camidge, Ross
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S238 - S239
  • [7] Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies
    Camidge, D. R.
    Bazhenova, L.
    Salgia, R.
    Weiss, G. J.
    Langer, C. J.
    Shaw, A. T.
    Narasimhan, N. I.
    Dorer, D. J.
    Zhang, J.
    Gettinger, S. N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S795 - S795
  • [8] UPDATED RESULTS OF A FIRST-IN-HUMAN DOSE-FINDING STUDY OF THE ALK/EGFR INHIBITOR AP26113 IN PATIENTS WITH ADVANCED MALIGNANCIES
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Weiss, Glen J.
    Langer, Corey J.
    Shaw, Alice T.
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Zhang, Joshua
    Clackson, Tim
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S296 - S297
  • [9] Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results
    Gettinger, S. N.
    Bazhenova, L. A.
    Salgia, R.
    Langer, C. J.
    Gold, K.
    Rosell, R.
    Shaw, A. T.
    Weiss, G. J.
    Dorer, D. J.
    Rivera, V. M.
    Kerstein, D.
    Camidge, D. R.
    LUNG CANCER, 2016, 91 : S20 - S21
  • [10] First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.
    Camidge, D. Ross
    Bazhenova, Lyudmila
    Salgia, Ravi
    Weiss, Glen J.
    Langer, Corey J.
    Shaw, Alice Tsang
    Narasimhan, Narayana I.
    Dorer, David J.
    Rivera, Victor M.
    Zhang, Joshua
    Clackson, Tim
    Haluska, Frank G.
    Gettinger, Scott N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345